BTIG raised the firm’s price target on Arvinas (ARVN) to $18 from $16 and keeps a Buy rating on the shares. Along with its Q1 results, the company announced it was selected by Rigel Pharmaceuticals (RIGL) as the third-party commercial partner for VEPPANU, receiving $85M upfront and up to $320M in future milestones, which removes the key commercial overhang, gets VEPPANU to patients, and provides Arvinas proceeds to reinvest into its wholly owned pipeline, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas price target raised to $20 from $18 at Barclays
- Arvinas Faces Key Commercialization Risk as VEPPANU’s Success Hinges on Third‑Party Partner with Pfizer
- Arvinas Earnings Call: PROTAC Breakthrough and New Risks
- H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
- Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu